These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20503071)

  • 21. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
    Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
    Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
    Aschele C; Debernardis D; Bandelloni R; Cascinu S; Catalano V; Giordani P; Barni S; Turci D; Drudi G; Lonardi S; Gallo L; Maley F; Monfardini S
    Ann Oncol; 2002 Dec; 13(12):1882-92. PubMed ID: 12453856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
    Chen Y; Xia X; Wang S; Wu X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Røe OD; Zhou J
    J Gastroenterol; 2013 Sep; 48(9):1034-44. PubMed ID: 23307041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
    Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
    Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
    BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
    Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
    Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
    De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of advanced gastric cancer with oxaliplatin plus 5-fluorouracil/ leucovorin (FOLFOX-4 chemotherapy)].
    Garrido M; Melgoza G; Galindo H; Madrid J; Sánchez C; Nervi B; Alvarez M; Orellana E
    Rev Med Chil; 2007 Nov; 135(11):1380-7. PubMed ID: 18259648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
    Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
    Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
    Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
    Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    Uchida K; Danenberg PV; Danenberg KD; Grem JL
    BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer].
    Zhao L; Li XY; Bai CM; Chen SC
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(18):1264-6. PubMed ID: 18844100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
    Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
    Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.